Understanding the association between narcolepsy and one of the 2009 adjuvanted influenza A (H1N1) vaccines
This meeting was designed to offer a place to exchange the latest information on into the development of narcolepsy following vaccination with one of the 2009 adjuvanted influenza A(H1N1) vaccines.
Risk assessment guidelines for infectious diseases transmitted on aircraft (RAGIDA): Influenza
This report which is part of the RAGIDA project (Risk Assessment Guidance for Infectious Diseases transmitted on Aircraft) provides viable options for decision-makers when faced with the choice of whether to contact trace air travellers and crew that were potentially exposed to infectious diseases during a flight.
- Avian influenza virus
- Infectious diseases on aircrafts
- Influenza A (H1N1)2009
- Influenza A(H5N1) virus
- Influenza A(H5N2) virus
- Influenza A(H5N8) virus
- Influenza A(H7N9) virus
- Influenza in humans, avian origin
- Influenza in humans, pandemic
- Influenza in humans, seasonal
- Influenza in humans, swine origin
- Risk assessment guidelines for infectious diseases transmitted on aircraft (RAGIDA)
- Travellers' health
Narcolepsy in association with pandemic influenza vaccination – a multi-country European epidemiological investigation
This report summarises the results from two epidemiological studies conducted by the Vaccine Adverse Event Surveillance and Communication (VAESCO) Consortium undertaken in eight European Union (EU)/European Economic Area (EEA) countries in order to investigate a possible association between an unexpected increase in narcolepsy cases following the use of influenza A(H1N1)pdm09 vaccines. Narcolepsy is an underdiagnosed disease of widely unknown etiology.
Chronological overview of the 2009/2010 H1N1 influenza pandemic and the response of the Centre for Infectious Disease Control (RIVM)Archived
The Centre for Infectious Disease Control (CIb) of the Dutch National Institute for Public Health and the Environment (RIVM) has compiled a chronological overview of that country’s response to the 2009 influenza A(H1N1) pandemic.
Issues around the definitions and severity of pandemic influenzaArchived
This collection of article is intended to clarify the issues that arose, during the 2009 pandemic around definitions of the pandemic term, both in a theoretical and practical way.
Recommendation by the European Medicines Agency concerning Pandemrix vaccination and reports of narcolepsy in children and adolescentsArchived
EMA recommends restricting use in persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.
EMA's Committee for Medicinal Products for Human Use (CHMP) issues opinion on narcolepsy and vaccination with Pandemrix®Archived
On 21 July 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued its opinion on the review of Pandemrix® and reports on narcolepsy. The CHMP recommended that in persons under 20 years of age Pandemrix® may only be used if the recommended seasonal trivalent influenza vaccine is not available and if immunisation against H1N1 is still needed (e.g. in persons at risk of the complications of infection).
European Parliament resolution on the evaluation of the management of H1N1 influenza in 2009-2010 in the EUArchived
The European Parliament adopted a resolution on the evaluation of the pandemic in its sitting on the 8th March 2011.